Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Onyema Ogbuagu(Brigham and Women's Hospital), Hadas Dvory‐Sobol(Gilead Sciences (United States)), Gary Richmond(University of Fort Lauderdale), Joseph P. McGowan, Krittaecho Siripassorn(Bamrasnaradura Infectious Diseases Institute), Catherine Creticos, Mezgebe Berhe, Ploenchan Chetchotisakd(Khon Kaen University), Antonella Castagna(Vita-Salute San Raffaele University), Winai Ratanasuwan(Siriraj Hospital), Nicolas Margot(Gilead Sciences (United States)), Francesco Castelli(University of Brescia), Theo Hodge, Jared M. Baeten(University of Washington), Christine Zurawski(New York Hospital Queens), Moti Ramgopal(Midway University), Sylvie Ronot-Bregigeon, James J. Sims(University of California, Riverside), Peter Ruane, Gordon Crofoot(Clinical Research Organization), Hui Wang(Weifang Maternity and Child Care Hospital), Daniel S Berger(University of Illinois Chicago), Edwin DeJesus(Orlando Immunology Center), Olayemi Osiyemi, Kenneth Lichtenstein(National Jewish Health), Martin S. Rhee(Gilead Sciences (United States)), William E. Sanchez, Cynthia Brinson, Gary Ian Sinclair, David A. Wheeler(Baylor College of Medicine), Debbie Hagins(Coastal Health District)
Cited by 71
Related Papers
The repertoire of mutational signatures in human cancer
|Nature|2020|3.8k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Somatic mutations affect key pathways in lung adenocarcinoma
|Nature|2008|2.8k